{
    "clinical_study": {
        "@rank": "1640", 
        "acronym": "PREVENT", 
        "arm_group": {
            "arm_group_label": "Percutaneous treatment for Tricuspid Regurgitation", 
            "arm_group_type": "Experimental", 
            "description": "TriCinch System"
        }, 
        "brief_summary": {
            "textblock": "The TriCinch System\u2122 is intended for percutaneous treatment of tricuspid regurgitation.\n\n      It is a percutaneous catheter-based device designed for tricuspid valve repair in order to\n      decrease effective cross-sectional area and relieve symptoms in patients with tricuspid\n      valve regurgitation."
        }, 
        "brief_title": "Percutaneous Treatment of Tricuspid Valve Regurgitation With the TriCinch System\u2122", 
        "completion_date": {
            "#text": "June 2015", 
            "@type": "Anticipated"
        }, 
        "condition": "Tricuspid Regurgitation", 
        "condition_browse": {
            "mesh_term": "Tricuspid Valve Insufficiency"
        }, 
        "detailed_description": {
            "textblock": "Implantation Procedure: Unlike the standard open chest, arrested heart approach, the 4TECH\n      TriCinch System\u2122 provides a percutaneous solution for tricuspid valve regurgitation\n      treatment: this procedure is performed through deep sedation, while the heart is beating,\n      without the need for respiratory assistance.\n\n      The TriCinch System\u2122 consists of a Delivery System that enables transcatheter placement of\n      an implant that can be adjusted to correct Tricuspid valve regurgitation. The TriCinch\n      Delivery System is inserted from the femoral vein to access the right atrium of the heart.\n      At the end of the correction process, the TriCinch Delivery System and the venous introducer\n      are removed and the procedure is concluded."
        }, 
        "eligibility": {
            "criteria": {
                "textblock": "Inclusion Criteria:\n\n          -  Functional symptomatic tricuspid regurgitation (TR) 2+ to 4+ on a scale of 4+\n             (moderate to severe), with annular dilatation greater than 40mm.\n\n          -  Signed informed consent form prior to any study-related procedure.\n\n          -  Available and able to return to the study site for post-procedural follow-up\n             examination\n\n          -  Eighteen (18) years of age or older.\n\n        Exclusion Criteria:\n\n          -  Requirement for concomitant cardiac procedure (other than atrial fibrillation\n             correction surgery, closure of PFO (Patent Foramen Ovale) or ASD (Atrial Septal\n             Defect), or PTCA (percutaneous treatment of coronary artery) or CAD (coronary artery\n             bypass surgery) from 1 to 3 months after or before other procedure.\n\n          -  Presence of any known life threatening (non-cardiac major or progressive disease),\n             non-cardiac disease that will limit the subject's life expectancy to less than one\n             year.\n\n          -  Cerebro-vascular event within the past 6 months.\n\n          -  History of mitral/tricuspid endocarditis within the last 12 months.\n\n          -  Organic tricuspid disease.\n\n          -  Contraindication  or  known  allergy  to  device's  components,  aspirin,\n             anti-coagulation therapy or contrast media that cannot be adequately premeditated.\n\n          -  Severe hypertension (SBP \u2265 180 mmHg and/or DBP \u2265 110 mmHg, measurement done by\n             sphygmomanometer with stethoscope, allow the patient to sit for at least 5 minutes\n             before beginning BP measurements).\n\n          -  Female patient is pregnant (urine HCG test result positive) or lactating.\n\n          -  Known alcohol or drug abuser.\n\n          -  Currently participating in the study of an investigational drug or device.\n\n          -  At heart team's judgement, patient IVC dimension is not adequate for device\n             implantation."
            }, 
            "gender": "Both", 
            "healthy_volunteers": "No", 
            "maximum_age": "N/A", 
            "minimum_age": "18 Years"
        }, 
        "enrollment": {
            "#text": "24", 
            "@type": "Anticipated"
        }, 
        "firstreceived_date": "March 13, 2014", 
        "has_expanded_access": "No", 
        "id_info": {
            "nct_id": "NCT02098200", 
            "org_study_id": "PREVENT_001/2013"
        }, 
        "intervention": {
            "arm_group_label": "Percutaneous treatment for Tricuspid Regurgitation", 
            "description": "Percutaneous treatment of Tricuspid Regurgitation", 
            "intervention_name": "TriCinch System", 
            "intervention_type": "Device"
        }, 
        "is_fda_regulated": "No", 
        "keyword": [
            "tricuspid", 
            "regurgitation", 
            "repair", 
            "outcomes"
        ], 
        "lastchanged_date": "March 25, 2014", 
        "location": [
            {
                "contact": {
                    "email": "jean-michel.juliard@bch.aphp.fr", 
                    "last_name": "JeanMichel Juliard", 
                    "phone": "0033140256735"
                }, 
                "contact_backup": {
                    "last_name": "Alec Vahanian", 
                    "phone": "0033140256760"
                }, 
                "facility": {
                    "address": {
                        "city": "Paris", 
                        "country": "France", 
                        "state": "Paris Cedex 18", 
                        "zip": "75877"
                    }, 
                    "name": "Bichat Hospital"
                }, 
                "investigator": [
                    {
                        "last_name": "Jean Michel Juliard", 
                        "role": "Principal Investigator"
                    }, 
                    {
                        "last_name": "Alec Vahanian", 
                        "role": "Sub-Investigator"
                    }
                ], 
                "status": "Recruiting"
            }, 
            {
                "contact": {
                    "email": "tambucor@unict.it", 
                    "last_name": "Corrado Tamburino", 
                    "phone": "0039095743201"
                }, 
                "facility": {
                    "address": {
                        "city": "Catania", 
                        "country": "Italy", 
                        "zip": "95124"
                    }, 
                    "name": "Ferrarotto Hospital"
                }, 
                "investigator": {
                    "last_name": "Corrado Tamburino", 
                    "role": "Principal Investigator"
                }, 
                "status": "Not yet recruiting"
            }, 
            {
                "contact": {
                    "email": "volkmar.falk@usz.ch", 
                    "last_name": "Valkmar Falk", 
                    "phone": "00410442553298"
                }, 
                "facility": {
                    "address": {
                        "city": "Zurich", 
                        "country": "Switzerland", 
                        "zip": "8006"
                    }, 
                    "name": "Universitaetsspital Zeurich"
                }, 
                "investigator": {
                    "last_name": "Volkmar Falk", 
                    "role": "Principal Investigator"
                }, 
                "status": "Not yet recruiting"
            }
        ], 
        "location_countries": {
            "country": [
                "France", 
                "Italy", 
                "Switzerland"
            ]
        }, 
        "number_of_arms": "1", 
        "official_title": "Percutaneous Treatment of Tricuspid Valve Regurgitation With the TriCinch System\u2122", 
        "other_outcome": {
            "description": "Compare to baseline at 6 months", 
            "measure": "Quality of Life assessment", 
            "safety_issue": "No", 
            "time_frame": "6 months"
        }, 
        "overall_contact": {
            "email": "colombo.antonio@hsr.it", 
            "last_name": "Antonio Colombo", 
            "phone": "00390226437102"
        }, 
        "overall_contact_backup": {
            "email": "alfieri.ottavio@hsr.it", 
            "last_name": "Ottavio Alfieri"
        }, 
        "overall_official": {
            "affiliation": "San Raffaele Hospital", 
            "last_name": "Antonio Colombo", 
            "role": "Principal Investigator"
        }, 
        "overall_status": "Recruiting", 
        "oversight_info": {
            "authority": [
                "Italy: National Monitoring Centre for Clinical Trials - Ministry of Health", 
                "France: Agence Nationale de S\u00e9curit\u00e9 du M\u00e9dicament et des produits de sant\u00e9", 
                "Switzerland: Swissmedic"
            ], 
            "has_dmc": "Yes"
        }, 
        "phase": "Phase 1", 
        "primary_completion_date": {
            "#text": "June 2015", 
            "@type": "Anticipated"
        }, 
        "primary_outcome": [
            {
                "description": "Freedom from major adverse event: death, Q-wave myocardial infarction, cardiac tamponade, cardiac surgery for failed TriCinch implantation, stroke, or septicaemia.", 
                "measure": "Safety: The percentage of participants with Major Adverse Events within 30 days of the procedure.", 
                "safety_issue": "Yes", 
                "time_frame": "Up to 30 days"
            }, 
            {
                "description": "Ability to reduce tricuspid regurgitation by at least 1 degree immediately following implantation of the TriCinch device assessed by means of quantitative echocardiographic parameters.", 
                "measure": "Performance: The reduction in degree of tricuspid regurgitation measured immediately after the  procedure compared to baseline.", 
                "safety_issue": "No", 
                "time_frame": "intraoperative"
            }, 
            {
                "description": "Ability to reduce tricuspid regurgitation by at least 1 degree immediately following implantation of the TriCinch device assessed by means of quantitative echocardiographic parameters.", 
                "measure": "Performance: The reduction in the degree of tricuspid regurgitation measured at time of discharge compared to baseline.", 
                "safety_issue": "No", 
                "time_frame": "Time of discharge - 5 days"
            }
        ], 
        "required_header": {
            "download_date": "ClinicalTrials.gov processed this data on June 04, 2014", 
            "link_text": "Link to the current ClinicalTrials.gov record.", 
            "url": "http://clinicaltrials.gov/show/NCT02098200"
        }, 
        "responsible_party": {
            "responsible_party_type": "Sponsor"
        }, 
        "secondary_outcome": [
            {
                "description": "Rate of device-related major adverse event (MAE).", 
                "measure": "Safety: The percentage of participants with Major Adverse Events up to 3 months of the procedure.", 
                "safety_issue": "Yes", 
                "time_frame": "3 months"
            }, 
            {
                "description": "Rate of device-related Major Adverse Event (MAE).", 
                "measure": "Safety: The percentage of participants with Major Adverse Events within 6 months of the procedure.", 
                "safety_issue": "Yes", 
                "time_frame": "6 months"
            }, 
            {
                "description": "Ability to maintain Tricuspid Regurgitation with respect to baseline.", 
                "measure": "Performance: Assessment in the degree of Tricuspid Regurgitation at 3 months compared to baseline.", 
                "safety_issue": "No", 
                "time_frame": "3 months"
            }, 
            {
                "description": "Ability to maintain Tricuspid Regurgitation with respect to baseline.", 
                "measure": "Performance: Assessment in the degree of Tricuspid Regurgitation at 6 months compared to baseline.", 
                "safety_issue": "No", 
                "time_frame": "6 months"
            }
        ], 
        "source": "4Tech Cardio Ltd.", 
        "sponsors": {
            "lead_sponsor": {
                "agency": "4Tech Cardio Ltd.", 
                "agency_class": "Industry"
            }
        }, 
        "start_date": "June 2013", 
        "study_design": "Allocation: Non-Randomized, Endpoint Classification: Safety Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment", 
        "study_type": "Interventional", 
        "verification_date": "March 2014"
    }
}